This approval is the outcome of the inspection of Goa Plant I, which was conducted in December 2016
Indoco Remedies received approval from UK-MHRA for its solid dosages manufacturing facility in Goa Plant I. This approval is the outcome of the inspection conducted in December 2016. The plant contributes to 40 per cent of their international business.
Commenting on the approval, Aditi Panandikar, MD, Indoco Remedies said, “The approval from UK MHRA for our Goa solid dosages facility will provide further impetus to our existing efforts in the European region”. This is the sixth time the Goa Plant I has successfully faced UK-MHRA inspection and received approval from time to time since 2003, thereby confirming Indoco’s consistent adherence to international standards and good manufacturing practices.